Inventors:
- La Jolla CA, US
- Tokyo, JP
David MILLS - Seattle WA, US
Rachel SOLOFF NUGENT - San Diego CA, US
Monica LEUNG - San Diego CA, US
Assignee:
La Jolla Institute for Allergy & Immunology - La Jolla CA
KYOWA HAKKO KIRIN CO., LTD - Tokyo
International Classification:
C07K 16/28
A61K 38/17
A61K 38/19
A61P 11/00
A61P 11/06
Abstract:
The present invention relates to a method and a medicament for airway and/or lung diseases such as moderate and/or severe asthma disease, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and systemic sclerosis. The medicament contains an agent which inhibits TL1A-DR3 interaction, and the method involves administering an effective amount of the agent to a subject to inhibit at least one symptom, feature or condition selected from hyperplasia of epithelial cells, epithelial metaplasia, hypertrophy of smooth muscle cells, and hyperproliferation of smooth muscle cells, production of extracellular matrix, and/or airway and/or lung tissue remodeling.